Pre-eclampsia

Definition

    • A hypertensive syndrome that occurs in pregnant women after 20 weeks' gestation

    • New-onset, persistent hypertension (defined as a BP of ≥140 mmHg systolic and/or ≥90 mmHg diastolic, based on at least 2 measurements taken at least 4 hours apart)

    • With proteinuria (defined as urinary excretion of ≥0.3 g protein/24 hours). [1] [2] [3]

    • The severity of the condition is based on the BP measurement and the presence of systemic involvement. [1] [2] [3]

Risk Factors

    • Strong

      • Primiparity

      • Pre-eclampsia in previous pregnancy

      • Family history of pre-eclampsia

      • Body mass index >30

      • Maternal age >35 years

      • Multiple (twin) pregnancy

      • Gestational hypertension

      • Pre-gestational diabetes

      • Autoimmune disease

      • Renal disease

      • Chronic hypertension

    • Weak

      • BP ≥80 mmHg diastolic at booking

      • Interval of 10 years or more since previous pregnancy

Differential diagnosis

Epidemiology

    • Pre-eclampsia has been reported to occur in about 5% to 8% of all pregnancies in the US. [3]

    • When figures include patients who develop pre-eclampsia postpartum, the incidence is between 4% to 6% of all pregnancies throughout the world. [4] [5]

    • The incidence of severe disease and complications varies.

      • Severe disease, which is associated with an increased risk of morbidity and mortality, has an incidence of only 0.5% in the developed world, [6]

      • Rises to 1% in low-income countries. [5]

      • Similarly, the incidence of complications such as eclampsia is also variable.

      • In the UK, the incidence has decreased from 4.9 per 10,000 per year in 1992 [7] to 3.89 per 10,000 per year by 2000. [5]

      • This decrease is observed mostly in the intrapartum and postpartum groups, suggesting a possible beneficial effect of prophylactic magnesium sulphate. [5]

      • However, in low-income countries the incidence of eclampsia is 10-fold greater, at about 50 per 10,000 per year. [6]

Aetiology

    • Pre-eclampsia is associated with a failure of normal invasion of trophoblast cells leading to maladaptation of maternal spiral arterioles

    • Associated with hyperplacentation disorders such as diabetes, hydatidiform mole, and multiple pregnancy. [8]

    • There are numerous risk factors that increase the probability and severity

      • However, these risk factors do not account for all cases

    • Complications such as eclampsia, HELLP syndrome, and fetal growth restriction are not present in all patients.

      • HELLP is a subtype of severe pre-eclampsia characterised by haemolysis (H), elevated liver enzymes (EL), and low platelets (LP)

Clinical features

    • Common

      • >20 weeks' gestation

      • BP ≥140 mmHg systolic and/or ≥90 mmHg diastolic and previously normotensive

      • headache

      • upper abdominal pain

      • reduced fetal movement

      • fetal growth restriction

      • oedema

    • Uncommon

      • visual disturbances

      • seizures

      • breathlessness

      • oliguria

      • hyper-reflexia and/or clonus

Pathophysiology

    • Pre-eclampsia is associated with a failure of the normal invasion of trophoblast cells leading to maladaptation of maternal spiral arterioles. [8]

      • The maternal arterioles are the source of blood supply to the fetus.

      • Maladaptation of these vessels can interfere with normal villous development leading to placental insufficiency and fetal growth restriction.

    • Abnormalities of spiral artery adaptation are immunologically based, with genetic influences. [4] [8]

    • Not all women with this potential placental trigger develop the syndrome

      • Therefore, the maternal response must be the decisive factor in development of systemic disease.

      • This systemic maternal response is what manifests itself as pre-eclampsia. [4]

    • Clinically, pre-eclampsia does not manifest until after 20 weeks' gestation.

    • However, more recent studies suggest that preclinical changes may occur, suggested by the presence of various biomarkers, although none are currently used in routine clinical practice. [4]

    • Hypertension and proteinuria are due to the vascular inflammatory response that produces vasoconstriction and capillary leak. [4]

    • Other presentations are complications of the vascular inflammation and capillary leak

      • eclampsia (due to cerebral vascular dysregulation and oedema)

      • HELLP syndrome (due to liver vascular dysregulation and oedema causing abdominal pain)

      • pulmonary oedema (due to capillary leak).

Investigations

    • urinalysis

      • 1+ protein; urinary excretion of ≥0.3 g protein in 24 hours; or urine protein:creatinine ratio ≥30 mg/mmol

    • fetal ultrasound

      • variable depending on severity

    • fetal cardiotocography

      • no abnormalities in tracing indicate assured fetal wellbeing

    • fetal biometry

      • may reveal fetal growth restriction

    • umbilical artery Doppler velocimetry

      • absence of end diastolic flow is a sign that delivery will probably be necessary in the near future

    • amniotic fluid assessment

      • deepest vertical pocket ≥2 cm implies normality; <2 cm is associated with increased fetal morbidity and delivery should be considered

    • FBC

      • low platelet count is partly diagnostic for HELLP syndrome

    • LFTs

      • Increased transaminase levels are partly diagnostic for HELLP syndrome.

    • Serum creatinine

      • Elevated serum creatinine implies underlying renal disease.

      • Renal failure is a rare complication, and when it occurs, it is usually acute tubular necrosis associated with co-existing sepsis or placental abruption

    • coagulation screen

      • May be abnormal with advanced disease affecting the liver, or in association with abruption

Management

    • Before delivery

      • hospital admission and monitoring

      • decision regarding delivery

        • At <32 weeks' gestation: prolonging the pregnancy is beneficial for the fetus, as long as maternal and fetal assessments are satisfactory

        • At >36 weeks' gestation: delivery is the most sensible approach

      • corticosteroid

        • Antenatal corticosteroids are recommended before 34 weeks' gestation to mature fetal lungs

      • consider for outpatient follow-up when stable

      • with BP ≥150 mmHg systolic and/or ≥100 mmHg diastolic

        • antihypertensive therapy

          • Labetalol is considered the antihypertensive of choice, [2] [3] and is effective as monotherapy in 80% of cases

          • Acceptable alternatives include methyldopa, nifedipine (a calcium-channel blocker), and hydralazine

      • with seizures

        • magnesium sulphate

    • After delivery

      • close monitoring of fluid balance

      • continue antihypertensives and magnesium sulphate

Prognosis

    • Pre-eclampsia is a self-limiting condition of pregnancy that usually resolves once the placenta has been delivered, although it may persist for a few days post delivery.

    • There are few long-term sequelae; however, there are some long-term disease associations.

    • The course of pre-eclampsia is altered by treatment, and the condition can be controlled easily in the majority of cases, usually within a few hours of starting treatment.

    • Once controlled, the length of the disease depends on when delivery is decided.

    • After delivery, the condition normally settles within 2 to 4 days; however, some women have hypertensive problems and proteinuria for some weeks after.

    • The overall risk of recurrence in subsequent pregnancies ranges from about 10% to 50%

      • Depending on the severity of pre-eclampsia, the gestation it occurred at, and subsequent interventions in the next pregnancy. [2] [2]

      • Generally, in previous severe or early onset (i.e., <30 weeks) pre-eclampsia, the risk of recurrence is 50%.

      • In mild to moderate or late-onset pre-eclampsia, the risk of recurrence is reduced to around 10%. [2]

    • There are good epidemiological data that suggest that women with pre-eclampsia have an increased long-term risk of cardiovascular disease, including hypertension and stroke. [2] [17]